Vaxxas and CEPI advance US$ 4.8 million programme for needle-free thermostable mRNA vaccines: Cambridge, Massachusetts Friday, January 24, 2025, 14:00 Hrs [IST] Vaxxas, a clinical ...

Vaxxas, a clinical-stage biotechnology company commercializing a novel high-density microarray patch (HD-MAP) vaccination platform, today announced that CEPI, the Coalition for Epidemic Preparedness ...

The first of two season-defining games for both Pitt and UNC will boil down to, in my mind, what each of their letters mean.

The Vaxxas HD-MAP is comprised of thousands of microscopic projections molded into a small patch. Each microprojection is coated with a small dose of vaccine in a dried formulation. When applied ...

Vaxxas has announced that the CEPI, has approved the progression of a $7.2 million program to develop heat-stable, ...

showing excellent thermostability and effective delivery of mRNA using Vaxxas’ proprietary high-density microarray patch (HD-MAP) technology. Vaxxas will partner with leading global vaccine ...

Serum Institute of India is planning to introduce chikungunya and monkeypox vaccines in about a year and a half and a dengue vaccine in approximately three years. The company is focusing on vaccine ...

[30] Patch testing with the whole vaccine, as well as with its individual components in standardized concentrations and vehicles, was performed on the skin after resolution of the reaction.

Audicana and colleagues evaluated tolerance to thimerosal-containing vaccines in 125 patients sensitized to mercury derivatives and/or thimerosal. [23] Patch-test results in this patient ...